1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Adderall XR faces first generic competition in US

 
• By Nancy Faigen

Teva Pharmaceutical Industries has launched its generic version of Shire's Adderall XR (amphetamine mixed salts) capsules in the US, in five strengths. Shire has been saying for some time that it expected an April 1st launch by Teva for the attention deficit hyperactivity disorder (ADHD) product. There is currently no generic competition in the US for the product.

Teva Pharmaceutical Industries has launched its generic version of Shire's Adderall XR (amphetamine mixed salts) capsules in the US, in five strengths. Shire has been saying for some time that it expected an April 1st launch by Teva for the attention deficit hyperactivity disorder (ADHD) product. There is currently no generic competition in the US for the product.

Shire is less reliant on Adderall XR now than it was in 2006 when the product accounted for 56% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Therapeutic Category

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.